Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ezetimibe/Simvastatin · Zetia, SCH-58235

Small molecule · Inhibitor of Niemann-Pick C1-Like 1 protein (NPC1L1) and HMG-CoA reductase (HMGCR) · developed by Organon

Approved FDA, Oct 2002
OGN Developer

What is Ezetimibe/Simvastatin?

Ezetimibe/simvastatin is a combination of ezetimibe, which binds the sterol transporter NPC1L1 at the small intestinal brush border to inhibit cholesterol absorption, and simvastatin, which after conversion to its active beta-hydroxyacid form competitively inhibits HMG-CoA reductase in cholesterol synthesis. It is studied in hypercholesterolemia and atherosclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Zetia, SCH-58235, MK0653, NSC-758923
Drug type
Small molecule
Targets
Niemann-Pick C1-Like 1 protein (NPC1L1), HMG-CoA reductase (HMGCR)
Mechanism
Inhibitor of Niemann-Pick C1-Like 1 protein (NPC1L1) and HMG-CoA reductase (HMGCR)
Pathways
intestinal cholesterol absorption, cholesterol synthesis (mevalonate pathway), hepatic LDL receptor upregulation
Therapy area
Cardiovascular, Metabolic
Developer
Organon (OGN)
FDA status
Approved as Zetia (October 25, 2002), NDA021445 · FDA label
UNII
EOR26LQQ24

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 25, 2025). Read the full label for the exact wording, limitations and safety information.

Conditions studied

AtherosclerosisHypercholesterolemia

Other drugs acting on NPC1L1 / HMGCR

More from Organon

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OGN page.

Follow OGN, the company behind Ezetimibe/Simvastatin

See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.